{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+interleukin-4", "query": { "intervention": "recombinant interleukin-4" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+interleukin-4&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T18:41:41.188Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006113", "title": "Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "recombinant CD40-ligand", "type": "BIOLOGICAL" }, { "name": "recombinant interferon gamma", "type": "BIOLOGICAL" }, { "name": "recombinant interleukin-4", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" }, { "name": "therapeutic tumor infiltrating lymphocytes", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" }, { "name": "Candida albicans skin test reagent", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "1999-06", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-09-13T18:41:41.188Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006113" }, { "nct_id": "NCT00001564", "title": "A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ewing's Sarcoma", "Rhabdomyosarcoma" ], "interventions": [ { "name": "EF-1 Peptide", "type": "DRUG" }, { "name": "EF-2 Peptide", "type": "DRUG" }, { "name": "PXFK Peptide", "type": "DRUG" }, { "name": "E7 Peptide", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "IL-4", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "CD40 Ligand", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 30, "start_date": "1996-12-23", "completion_date": "2007-10-25", "has_results": false, "last_update_posted_date": "2019-11-29", "last_synced_at": "2026-09-13T18:41:41.188Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001564" }, { "nct_id": "NCT00000769", "title": "A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "Interleukin-4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 48, "start_date": null, "completion_date": "1998-04", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-09-13T18:41:41.188Z", "location_count": 3, "location_summary": "Los Angeles, California • Boston, Massachusetts", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000769" }, { "nct_id": "NCT05720325", "title": "Dupilumab Effects Against Aeroallergen Challenge", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma, Allergic" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "House Dust Mites (HDM)", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 96, "start_date": "2023-03-29", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-13T18:41:41.188Z", "location_count": 2, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05720325" }, { "nct_id": "NCT00923910", "title": "Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Acute Myelogenous (AML)", "Leukemia, Acute Lymphocytic (ALL)", "Leukemia, Chronic Myelogenous (CML)", "Myelodysplastic Syndrome (MDS)", "Non-Hodgkin's Lymphoma (NHL)" ], "interventions": [ { "name": "WT1 Peptide-Pulsed Dendritic Cells", "type": "DRUG" }, { "name": "Donor Lymphocytes", "type": "DRUG" }, { "name": "IL-4", "type": "DRUG" }, { "name": "KLH", "type": "DRUG" }, { "name": "WT1 Peptides", "type": "DRUG" }, { "name": "Endotoxin", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "74 Years", "sex": "ALL", "summary": "1 Year to 74 Years" }, "enrollment_count": 10, "start_date": "2008-02-22", "completion_date": "2016-11-15", "has_results": true, "last_update_posted_date": "2017-04-12", "last_synced_at": "2026-09-13T18:41:41.188Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923910" }, { "nct_id": "NCT00039052", "title": "Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Kidney Cancer", "Lung Cancer" ], "interventions": [ { "name": "interleukin-4 PE38KDEL cytotoxin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Neurocrine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-01", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-09-13T18:41:41.188Z", "location_count": 2, "location_summary": "Tucson, Arizona • Los Angeles, California", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039052" }, { "nct_id": "NCT05094570", "title": "Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Nasal Polyps", "Staphylococcus Aureus" ], "interventions": [ { "name": "Dupilumab Prefilled Syringe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2022-09-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-09-13T18:41:41.188Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05094570" }, { "nct_id": "NCT02858895", "title": "Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Grade IV Astrocytoma", "Glioblastoma Multiforme", "Grade IV Glioma" ], "interventions": [ { "name": "MDNA55", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicenna Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2017-04-11", "completion_date": "2019-10-31", "has_results": true, "last_update_posted_date": "2022-10-24", "last_synced_at": "2026-09-13T18:41:41.188Z", "location_count": 7, "location_summary": "San Francisco, California • Santa Monica, California • Boca Raton, Florida + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02858895" }, { "nct_id": "NCT06385236", "title": "Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Moderate to Severe Asthma" ], "interventions": [ { "name": "Dupilumab", "type": "BIOLOGICAL" }, { "name": "Benralizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 120, "start_date": "2024-02-19", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2024-08-19", "last_synced_at": "2026-09-13T18:41:41.188Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06385236" }, { "nct_id": "NCT00003842", "title": "IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "interleukin-4 PE38KDEL cytotoxin", "type": "BIOLOGICAL" }, { "name": "isolated perfusion", "type": "DRUG" }, { "name": "surgical procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Barrett Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "1999-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-09-13T18:41:41.188Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003842" } ] }